Loading...

The annual Enforcement, Litigation, and Compliance Conference brings together industry, regulators, attorneys, litigators, academics, and consultants to discuss trends and issues in enforcement and compliance, the latest developments in both civil and criminal litigation, and recent cases and settlements. This conference offers an opportunity to hear from and interact with top officials from FDA, DOJ, FTC, and other government agencies. 

Keynote Speakers:

  • Scott Gottlieb, Commissioner of Food and Drugs, FDA
  • James Burnham, Deputy Assistant Attorney General, Consumer Protection Branch, US Department of Justice
  • Stacy Cline Amin, Chief Counsel, FDA

Blumberg Lecturer:

  • Elizabeth Dickinson, Senior Deputy Chief Counsel, Office of Chief Counsel, FDA

Attendees Will:

  • Explore the latest trends behind enforcement actions in food, drugs, biologics, medical devices, and tobacco
  • Gain practical tips and best practices for responding to enforcement action by FDA or other government agencies
  • Learn how to comply with new and upcoming FDA rules and regulations
  • Hear about top issues, priorities, and goals for 2019 directly from ORA and FDA’s Center Compliance Directors, including:
    • Donald Ashley, Director, Office of Compliance, CDER
    • William Maisel, Director, Office of Device Evaluation and Acting Director, Office of Compliance, CDRH
    • Melissa Mendoza, Deputy Director, Office of Compliance and Biologics Quality, CBER
    • William Correll, Director, Office of Compliance, CFSAN
    • Ann Simoneau, Director, Office of Compliance and Enforcement, CTP
    • Eric M. Nelson, Director, Division of Compliance, CVM
    • Ellen F. Morrison, Assistant Commissioner for Medical Products and Tobacco Operations, Office of Regulatory Affairs, FDA
    • Michael Rogers, Assistant Commissioner for Human and Animal Food Operations, Office of Regulatory Affairs, FDA

Register

Industry & Firms

$1299
  • +$400 for non-members

Non-Profit

$999
  • +$100 for non-members

Government

$999
  • +$100 for non-members

Academic

$999
  • +$100 for non-members

Student

$99
  • student registration
Register Now

To ensure that FDLI is able to provide you with a seat, materials, and meals, please register for programs at least 48 hours in advance. While onsite registration is available on a “space-available” basis; late registrants are not guaranteed materials or meals.

You can transfer your registration to another person at your organization for no cost by notifying us of the change. If you notify FDLI in writing at least five business days prior to the meeting, you can cancel your registration for a full refund (less a $75 fee). Refunds will be applied against the original form of payment.  

Our event policies are listed here. If you should have any further questions, please contact us at [email protected] or 800-956-6293.

Call for Proposals

FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals this summer. The input received from industry stakeholders helps us plan a timely program. If you submitted a proposal, you will be notified of the status of your proposal in September.

Premier Sponsor

Diamond Sponsor

Gold Sponsor

Gold Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

Bronze Sponsor

Bronze Sponsor

Bronze Sponsor

Exhibitor

Agenda

Subject to Change

Wednesday, December 12

8:00–8:45 AM                
Registration and Continental Breakfast

8:45–9:00 AM
Welcome and Opening Remarks
Amy Comstock Rick, President & CEO, Food and Drug Law Institute
George M. Karavetsos, Partner, DLA Piper LLP and Chair, FDLI Enforcement, Litigation, and Compliance Conference

9:00–9:25 AM                 
Keynote Address
Scott Gottlieb, Commissioner of Food and Drugs, FDA

9:25–10:35 AM              
Compliance Central with FDA Center Compliance Directors: Part I
This two-part session will address FDA’s top compliance issues, enforcement priorities, and goals for 2019. Hear directly from each FDA Center Compliance Director, learn how industry should focus its compliance efforts, and what to expect when you don’t follow FDA regulations.

Donald Ashley, Director, Office of Compliance, Center for Drug Evaluation and Research, FDA
William H. Maisel, Director, Office of Device Evaluation and Acting Director, Office of Compliance, Center for Devices and Radiological Health, FDA
Melissa Mendoza, Deputy Director, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, FDA
Ellen F. Morrison, Assistant Commissioner for Medical Products and Tobacco Operations, Office of Regulatory Affairs, FDA
Moderated by Deborah M. Autor, SVP/Head of Strategic Global Quality & Regulatory Policy, Mylan Pharmaceuticals, Inc.

10:35–10:50 AM            
Coffee and Networking Break                                            

10:50 AM–12:00 PM            
Compliance Central with FDA Center Compliance Directors: Part II

Eric M. Nelson, Director, Division of Compliance, Center for Veterinary Medicine, FDA
Michael W. Roosevelt, Deputy Director, Office of Compliance, Center for Food Safety and Applied Nutrition, FDA
Michael C. Rogers, Assistant Commissioner for Human and Animal Food Operations, Office of Regulatory Affairs, FDA 
Ann L. Simoneau
, Director, Office of Compliance and Enforcement, Center for Tobacco Products, FDA
Moderated by John R. Manthei, Partner, Latham & Watkins LLP

12:00–1:15 PM            
Luncheon Address
Stacy Cline Amin
, Chief Counsel, FDA
Introduced by Jennifer L. Bragg, Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Vice Chair, FDLI Board of Directors

1:15–2:10 PM                 
Concurrent Sessions: 

  • Delaying, Denying, Limiting, or Refusing Inspections: How to Prepare
    In this session, speakers will discuss new developments and how FDA’s authority has been used when an establishment delays, denies, limits, or refuses an inspection. Speakers will delve into how to raise legitimate questions about FDA requests for information, as well as how to effectively say no. The recent extension of FDA’s authority to devices and implications for foreign inspections will also be addressed.

    Daniel G. Jarcho, Partner, Alston & Bird LLP
    Paula Katz, Special Counsel, Covington & Burling LLP
    Deborah Tolomeo, Senior Advisor, Global Quality and Compliance, Genentech, Inc.
    Moderated by William A. McConagha, Partner, Sidley Austin LLP

  • Looking Forward: OTC Drug Compliance
    What is FTC’s current thinking on homeopathic drugs? Will the trend of increasing GMP oversight for foreign and domestic OTC drug manufacturers continue? What questions are OTC drug clients asking their lawyers? How would the proposed legislation to reform the OTC monograph system affect FDA’s enforcement policies? Panelists will tackle these questions and more during this session.

    Richard Cleland, Assistant Director, Bureau of Consumer Protection, Division of Advertising Practices, Federal Trade Commission
    Francis Godwin, Acting Director, Office of Manufacturing Quality, Center for Drug Evaluation and Research, FDA
    Christine E. Kirk, Associate, Arnall Golden Gregory LLP
    Moderated by David J. Horowitz, Partner, Hogan Lovells US LLP

  • Consumer Fraud Cases in Food and Drugs
    One of the original goals of the FDCA was to protect consumers from fraud. Recently, we are seeing the agency think about fraud more. In what ways are we seeing the government use this function, for example in consumer confusion cases? What types of claims are sticking? This panel will explore FDA’s authority and actions in this area, as well as look to other statutes and agencies that are also active in protecting consumers from fraud.

    August T. Horvath
    , Partner, Foley Hoag LLP
    John F. Johnson
    , Senior Associate Attorney, FDAImports.com LLC / Benjamin L. England & Associates LLC
    Megan L. Olsen, Assistant General Counsel, Council for Responsible Nutrition

2:10–2:15 PM
Transition

2:15–3:10 PM                 
Concurrent Breakout Sessions:

  • The Benefits and Risks of Internal Audits and Investigations
    In many of its warning letters, the FDA calls on firms to use independent technical consultants to remediate compliance problems. Often, internal investigations produce reports that in part assess the scope of problems and recommend possible solutions. What information as part of that audit is required, or not required, to be turned over to FDA? What are the pros and cons of having a privileged investigation vs. having a consultant? The impact on consent decrees and use of independent experts will also be addressed.

    Thomas J. Cosgrove
    , Partner, Covington & Burling LLP
    John Geissler, Global Head, Compliance, Incident Management and Audit, Novartis
    Frances M. Zipp
    , President & CEO, Lachman Consultant Services, Inc.
    Moderated by Howard R. Sklamberg, Partner, Akin Gump Strauss Hauer & Feld LLP

  • Emerging Trends in State and Federal Opioid Investigations and Prosecutions
    The opioid epidemic has ignited a firestorm of actions and reactions by government and private actors alike. Federal and state governments have filed lawsuits against actors in the drug supply chain and qui tam whistleblowers are active in the private sector. This presentation will provide an overview of regulatory and enforcement actions taken by various public and private actors in response to the opioid epidemic and what all stakeholders in the drug supply chain need to know given the recent passage of the opioid legislation.

    George M. Karavetsos, Partner, DLA Piper LLP and Chair, FDLI Enforcement, Litigation, and Compliance Conference
    Kerry Mannion, Special Agent in Charge, Office of Criminal Investigations, FDA
    Moderated by Jonathan E. Levitt, Co-Founding Partner; Attorney, Frier & Levitt

  • Unique Compliance and Enforcement Issues with Cell and Gene Therapies
    In the last year, FDA has approved several novel gene therapy products, including the first chimeric antigen receptor (CAR) T cell therapy. The agency also published a suite of guidance documents related to cell and gene therapy in July 2018 and several on regenerative medicine in the fall of 2017. This panel will take a legal and regulatory look at the questions surrounding how to maintain robust quality during manufacturing and how FDA can effectively maintain appropriate oversight without discouraging innovation as more complex cell and gene therapy products are approved.

    Barbara A. Binzak Blumenfeld, Shareholder, Buchanan Ingersoll & Rooney PC
    Areta Kupchyk
    , Partner, Foley Hoag LLP
    Mark Levi
    , Senior Consultant, RCS Regulatory, Parexel International
    Moderated by 
    Kalah Auchincloss, Senior Vice President, Regulatory Compliance, and Deputy General Counsel, Greenleaf Health, Inc.

3:10–3:30 PM                 
Coffee and Networking Break

3:30–4:30 PM                 
Imports and International Considerations: Enforcement Trends and Updates
As business and manufacturing becomes increasingly global in nature, so do enforcement and compliance issues. During this panel, speakers will address a variety of top-of-mind international considerations and concerns. Topics include: FDA’s approach to imports and review strategies; mutual reliance initiatives; the difficulties of importing from the manufacturer perspective; and updates on FDA’s FSVP and VQIP programs for food products.

Kimberly Trautman, Executive Vice President, Medical Device International Services, NSF International
Domenic Veneziano, Independent Advisor for Import Operations, EAS Consulting Group, LLC
John Verbeten, Director, Division of Import Operations, Office of Regulatory Affairs, FDA
Moderated by Robert Guzman, Counsel, Thompson Hine LLP

4:30–5:30 PM
Top FDA Enforcement Cases in 2018
This session will consider the top enforcement cases and settlements of the past year and the potential implications for industry. Consequences of FDCA violations, big dollar settlements, and areas of enforcement to keep an eye on for the future will be discussed.

William F. Gould, Partner, Holland & Knight LLP
Pete Leininger, Counsel, King & Spalding LLP
Jeffrey Steger, Senior Counsel for Complex Litigation, Consumer Protection Branch, US Department of Justice
Moderated by Anne Walsh, Director, Hyman, Phelps & McNamara, PC

5:30–7:30 PM                 
FDLI 2018 Annual Holiday Reception

Thursday, December 13

8:30–8:55 AM                
Registration and Continental Breakfast

8:55–9:00 AM                 
FDLI Welcome and Remarks
Laura Brown, Director, Educational Programs, Food and Drug Law Institute

9:00–9:45 AM                
Keynote Address
James Burnham, Deputy Assistant Attorney General, Civil Division, Consumer Protection Branch, US Department of Justice

9:45–10:45 AM              
What are the DOJ Enforcement Trends Regarding FDA-Regulated Companies?
While DOJ has frequently said it will continue to go after fraud in the healthcare space, do recent memos and policy positions give FDA-regulated companies additional breathing room from the sorts of white-collar fraud actions that have previously loomed large? For example, what does the Brand Memo  which indicates that the government will not rely on agency guidance as the basis for enforcement  mean for allegations related to misbranding? What about the policy against “piling on” to prevent duplicative penalties? This panel will discuss recent enforcement trends and policy pronouncements, and possible implications and key takeaways for FDA-regulated companies.  

Lisa M. Dwyer, Partner, King & Spalding LLP
Gustav W. Eyler, Acting Director, Consumer Protection Branch, US Department of Justice
Brandon Moss, Associate, Wiley Rein LLP
Michele Sartori, Partner, Hogan Lovells US LLP
Moderated by Michael S. Blume, Partner, Venable LLP

10:45–11:00 AM            
Coffee and Networking Break

11:00–11:55 AM            
Concurrent Breakout Sessions:

  • Responding to Data Integrity Issues and Best Practices
    Data integrity continues to be a key focus of FDA inspection and enforcement activity, and collateral impacts from FDA enforcement are also increasing. Panelists will review best practices for responding to FDA data integrity inspection and enforcement findings and will briefly explore topics including: the relationship between Good Clinical Practice and data integrity, potential impacts to product approval from data integrity deficiencies, working with contract manufacturers, challenges for dietary supplement manufacturers, and data integrity challenges in litigation.
     
    Cathy L. Burgess, Partner, Alston & Bird LLP
    Douglas B. Farquhar, Director, Hyman, Phelps & McNamara, PC
    Cynthia Schnedar, Executive Vice President, Regulatory Compliance, Greenleaf Health, Inc.
    Moderated by John C. (Jack) Garvey, Principal/Chief Executive Officer, Compliance Architects LLC

  • REMS as an Enforcement Tool
    While FDA’s REMS authority has historically been touted as a measure to ensure the safe use of certain medications, FDA and DOJ have begun to use REMS compliance as an enforcement tool. In the past year, a company’s alleged non-compliance with REMS requirements has been deployed as a theory of criminal misbranding, and two cases have been settled. This panel will discuss how REMS has been used as an enforcement tool and what companies can do to ensure they are complying with their obligations.

    Jennifer L. Bragg, Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Vice Chair, FDLI Board of Directors
    Rachel Turow, Executive Counsel – Regulatory Law, Teva Pharmaceuticals USA, Inc.

  • Tobacco Enforcement Challenges and Recent Actions
    Since FDA’s announcement of its comprehensive plan for nicotine and tobacco regulation last summer, much has changed in both the marketplace and FDA’s approach. In particular, there are struggles with how to address concerns about youth appeal and uptake while maintaining focus on the continuum of risk. FDA has taken numerous high-profile enforcement actions and has threatened others, including a change in its enforcement discretion policy for “deemed products.” Are these actions consistent with the Agency’s statutory authority? Do they effectively address the youth uptake concerns? Will there be unintended consequences to this enforcement approach, such as the creation of black markets or negative impacts on smoking rates?

    Tony Abboud
    , Executive Director, Vapor Technology Association
    Stacy L. Ehrlich
    , Partner, Kleinfeld, Kaplan & Becker, LLP and Member, FDLI Board of Directors
    Beth G. Oliva, Partner, Fox Rothschild LLP

11:55–12:00 PM
Transition 

12:00–1:00 PM              
Concurrent Breakout Sessions:

  • Managing a Recall: Preparing for Regulatory and Legal Implications
    Rarely a day goes by without a product recall notification, be it food with undeclared allergens, drugs with foreign materials, or devices that are mislabeled. This past year even saw FDA’s first-ever mandatory recall under the Food Safety Modernization Act. Despite the expectation that companies prepare in advance for a potential recall, often companies are left flatfooted in addressing issues beyond those related to regulatory requirements. This session will recap regulatory obligations and anticipated interactions with FDA, as well as address handling of recall-related issues, such as recall publicity, insurance issues, and consequential litigation.

    Steven H. Armstrong
    , Independent Advisor, Food Law & Regulation, EAS Consulting Group, LLC
    Victoria Calhoon, Attorney, Faegre Baker Daniels LLP
    Matthew L. Jacobs, Of Counsel, Jones Day
    Mark Mansour, Partner, Foley Hoag LLP

  • False Claims Act Enforcement, Policy Updates, and Trends in Patient Support
    This panel will delve into recent False Claims Act (FCA) enforcement actions, which are often used to combat fraud and abuse in the healthcare space. Panelists will consider recent key cases and updates, including in the materiality standard, and whether companies can expect more FCA cases after Escobar. There has also been explosive attention in recent FCA enforcement surrounding reimbursement support activities by pharmaceutical manufacturers – panelists will discuss the unique risks associated with such activities, including best practices and compliance considerations for planning, implementing, and executing compliant reimbursement support activities and programs.

    Hannah Bornstein, Partner, Nixon Peabody LLP
    Abraham Gitterman, Associate, Arnold & Porter LLP
    Jonathan M. Phillips, Partner, Gibson, Dunn & Crutcher LLP

1:00–2:15 PM
Luncheon Address: Sixth Annual Eric M. Blumberg Memorial Lecture
Elizabeth H. Dickinson
, Senior Deputy Chief Counsel, Office of Chief Counsel, FDA
Introduced by Jeffrey N. Gibbs, Director, Hyman, Phelps & McNamara, PC and Chair, FDLI Board of Directors

2:15 PM                           
Conference Adjournment

2018 Planning Committee

Deborah Autor, Mylan
Jack Garvey, Compliance Architects LLC
George Karavetsos, DLA Piper
Mark Mansour, Foley Hoag LLP
Matthew Newcomer, Post & Schell PC
Cynthia Schnedar, Greenleaf Health LLC
Howard Sklamberg, Akin Gump
Kim Trautman, NSF Health Sciences
Anne Walsh, Hyman Phelps & McNamara PC
Jessica Zeller, FDA/ORA

Continuing Legal Education

FDLI applies for CLE credits in Ohio, Pennsylvania, and Virginia. These CLE approvals may also be honored by other states; please check with your bar association for guidance. The CLE credits will be posted as they are granted and you can request to be notified when approval is received.

Pennsylvania: approved for 10.0 CLE credit hours

Conference Location

JW Marriott
1331 Pennsylvania Ave NW
Washington, DC 20004

Overnight Accommodations

The FDLI group rate the JW Marriott is sold out. Reservations can be made online and are subject to prevailing rates and availability.

Driving, Parking, and Public Transportation

The JW Marriott is a short walk from Metro Center.   Valet parking is available for $59 each day. Parking garages are also available nearby.

2018-12-07T15:57:31+00:00